{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002306","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.328348+00:00","generated_at":"2026-05-16T11:05:19.894745+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Liquidia reports preliminary 2025 YUTREPIA net sales of $148.3M; Q4 sales $90.1M","bullets":["Q4 2025 YUTREPIA net sales ~$90.1M; full-year 2025 net sales ~$148.3M, up 74% QoQ.","Over 2,800 unique patient prescriptions since June 2025 launch; 85% conversion rate (Nov 2025).","Generated >$30M positive cash flow in Q4 2025; cash and equivalents ~$190.7M as of Dec 31.","Plan to expand field sales team in 2026; initiated multiple clinical studies for YUTREPIA and L606.","Preliminary results to be followed by audited full-year financials in Feb 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002306","json":"https://secwatch.observer/filing/0001104659-26-002306.json","markdown":"https://secwatch.observer/filing/0001104659-26-002306.md","text":"https://secwatch.observer/filing/0001104659-26-002306.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465926002306/0001104659-26-002306-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465926002306/tm262716d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:05:19.894745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}